Respiratory Drive on Obstructive Apnea

NCT ID: NCT01961648

Last Updated: 2015-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to determine whether inhaling exhaled carbon dioxide is effective for the treatment of sleep apnea. A mild increase in this gas can stimulate the respiratory drive by 2-3 fold, which in turn can stimulate the upper airway dilator muscles and decrease the severity of obstructive sleep apnea by at least 50% in selected patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During wakefulness pharyngeal dilator muscles (dilators) provide the necessary force to permit an adequate flow in all subjects regardless of how collapsible their passive pharynx is. This dilator activity is substantially lost at sleep onset. Subjects in whom the passive pharynx cannot permit adequate ventilation must recruit dilators through reflex mechanisms if they are to remain asleep. Dilators can be recruited reflexly via changes in blood gas tensions and in afferent activity of pharyngeal mechanoreceptors.

Patients with obstructive sleep apnea (OSA) develop repetitive obstructive events during which air flow decreases substantially (hypopneas) or ceases altogether (apneas). These last from 10 to \>60 seconds following which there is a substantial increase in ventilation (hyperventilatory phase) that lasts for several breaths. The cycle then repeats. Arousal from sleep occurs at some point during the hyperventilatory phase in the vast majority of obstructive respiratory events. However it has been shown that in the majority of OSA patients, the reflex mechanisms are competent and can deal with the obstruction without arousal. The respiratory drive must increase a finite amount before the upper airway muscles begin responding to increasing respiratory drive, and often the patient wakes up first. Thus, when a subject with a narrowed or more compliant pharynx falls asleep and obstructs his/her airway, blood gas tensions must deteriorate a threshold amount before the pharyngeal dilators begin responding. Once this threshold is reached, the dilators respond briskly to further changes in blood gas tensions and open the airway. This threshold was termed the Effective Recruitment Threshold (TER).

The basis for this research project is that if respiratory drive can be maintained at or near the threshold, the dilators would respond promptly to any obstruction and there would be little further increase in respiratory drive during obstruction.We estimate that the required increase in drive can be attained by simply raising carbon dioxide pressure (PCO2) 2-3 mmHg, a highly tolerable increase. We intend to increase respiratory drive on a continuous basis, beginning before sleep by asking the participants to breath through a regular continuous positive airway pressure (CPAP) mask with added dead space.

To increase dead-space we will modify commercial rebreathing bags used for oxygen therapy so that the amount of rebreathing can be adjustable. This should raise arterial carbon dioxide pressure (PaCO2) a few millimetres of mercury (mmHg) in the steady state. Upon sleep, the respiratory drive would be at or above TER in nearly half the patients. Should the airway obstruct, the dilator muscles would be in a position to respond promptly, preventing an acute further rise in respiratory drive. This will reduce the frequency of obstructive respiratory events by \>50% in at least half the patients, and improve sleep quality and nocturnal oxygen saturation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dead space

Participant will sleep connected to a mask with added dead space half of the night

Group Type ACTIVE_COMPARATOR

Rebreathing bag

Intervention Type DEVICE

Mask

Intervention Type DEVICE

room air

Participant will sleep connected to a mask open to rrom air, half of the night

Group Type SHAM_COMPARATOR

Sham rebreathing

Intervention Type DEVICE

Mask

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rebreathing bag

Intervention Type DEVICE

Sham rebreathing

Intervention Type DEVICE

Mask

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CO2 rebreathing Dead space Room air

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to severe OSA Apnea Hypopnea Index \> 20/hr.
* Minimum oxygen saturation by pulse oximetry (SpO2) during events \>70% throughout sleep during the clinical sleep study

Exclusion Criteria

* Neuromuscular disease.
* Obesity-hypoventilation syndrome.
* Chronic obstructive pulmonary disease.
* Pregnancy.
* Significant comorbidities:

1. Dialysis-dependant renal failure
2. Severe asthma
3. Congestive
4. Heart failure
5. Previous stroke
* Recent (within 3 months) myocardial infarction or Active coronary ischemia event.
Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Manitoba

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Misericordia Medical Centre, Sleep Disorder Centre

Winnipeg, Manitoba, Canada

Site Status

Sleep Disorder Centre at Misericordia Health Centre

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2012:132

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Myofunctional Therapy for Obstructive Sleep Apnea
NCT07301125 NOT_YET_RECRUITING NA